Elevation drops sole clinical-stage ADC over poor phase 1 data, lays off 70% of staff
Elevation is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the antibody-drug conjugate company to lay off 70% of its staff.
Elevation is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data, leading the antibody-drug conjugate company to lay off 70% of its staff.
